XML 15 R2.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Pay vs Performance Disclosure - USD ($) | 12 Months Ended
--- | ---
Oct. 31, 2023 | Oct. 31, 2022 | Oct. 31, 2021
Pay vs Performance Disclosure [Table] |  |  |  |
Pay vs Performance [Table Text Block] |  | Pay Versus Performance
|  |  |  |  |  | Average summary compensation |  | Average compensation actually paid |  | Value of initial fixed $100 investment based on: |  |  |  |
Year |  | Summary compensation table total for PEO |  | Compensation actually paid to PEO |  | table total for non-PEO named executive officers |  | to non-PEO named executive officers |  | Total Shareholder return |  | MSCI US Semi & Semi Equipment GICS Index |  | Net income ($Million) |  | Revenue ($Million)
(a) |  | (b) |  | (c) |  | (d) |  | (e) |  | (f) |  | (g) |  | (h) |  | (i)
|  | (1) |  | (2) |  | (3) |  | (4) |  |  |  |  |  |  |  |  |  |  |  |
2023 |  | 4,061,200 |  | 168,462 |  | 4,611,901 |  | 168,462 |  | 1,476,328 |  | 1,844,174 |  | 188.31 |  | 179.40 |  | 125.5 |  | 892.1
2022 |  | 2,924,350 |  | 2,470,279 |  | 2,948,823 |  | 482,294 |  | 1,606,992 |  | 1,619,472 |  | 166.36 |  | 109.88 |  | 118.8 |  | 824.5
2021 |  | 1,272,800 |  | 2,006,994 |  | 1,417,864 |  | 1,471,055 |  | 1,067,949 |  | 1,123,199 |  | 133.24 |  | 158.40 |  | 55.4 |  | 663.8
| (1) | Amounts shown are the amounts of total compensation reported for Dr. Lee, our CEO, for column of the Summary Compensation Table (SCT).
| (2) | Amounts shown are the amounts of total compensation reported for Dr. Kirlin, our former CEO, for column of the Summary Compensation Table (SCT).
| (3) | Amounts shown above include the compensation actually paid to Dr. Lee, our CEO.
| (4) | Amounts shown above include the compensation actually paid to Dr. Kirlin, our former CEO.
| (1) | Amounts shown are the amounts of total compensation reported for Dr. Lee, our CEO, for column of the Summary Compensation Table (SCT).
| (2) | Amounts shown are the amounts of total compensation reported for Dr. Kirlin, our former CEO, for column of the Summary Compensation Table (SCT).
Compensation actually paid to PEO (3)
Year | Salary | Bonus | The fair value as of the end of the covered year for all stock and option awards that were granted during the year and that remain unvested as of the end of the covered year. | The change in fair value (whether positive or negative) as of the end of the covered year for any awards granted in any prior fiscal year that remain outstanding and unvested as of the end of the covered year. | The fair value as of the vesting date for any awards that were granted and vested in the covered fiscal year. | The change in fair value (whether positive or negative) as of the vesting date of any awards granted in any prior year for which all applicable vesting conditions were satisfied during the covered year. | Total
(a) | (b) | (c) | (d) | (e) | (f) | (h) | (i)
2023 | 750,000 | 1,300,000 | 2,203,200 | 289,688 | 0 | 69,013 | 4,611,901
2022 | 650,000 | 963,800 | 1,216,500 | 242,213 | 0 | (123,690) | 2,948,823
2021 | 459,530 | 365,000 | 454,650 | 128,335 | (165) | 10,514 | 1,417,864
| (3) | Amounts shown above include the compensation actually paid to Dr. Lee, our CEO.
Compensation actually paid to PEO (4)
Year | Income | Bonus | The fair value as of the end of the covered year for all stock and option awards that were granted during the year and that remain unvested as of the end of the covered year. | The change in fair value (whether positive or negative) as of the end of the covered year for any awards granted in any prior fiscal year that remain outstanding and unvested as of the end of the covered year. | The fair value as of the vesting date for any awards that were granted and vested in the covered fiscal year. | The change in fair value (whether positive or negative) as of the vesting date of any awards granted in any prior year for which all applicable vesting conditions were satisfied during the covered year. | Total
(a) | (b) | (c) | (d) | (e) | (f) | (h) | (i)
2023 | 168,462 | 0 | 0 | 0 | 0 | 0 | 168,462
2022 | 735,079 | 0 | 0 | 0 | 0 | (252,785) | 482,294
2021 | 649,544 | 425,000 | 0 | 299,925 | 0 | 96,586 | 1,471,055
| (4) | Amounts shown above include the compensation actually paid to Dr. Kirlin, our former CEO.
Company Selected Measure Name |  | Revenue |  |
Named Executive Officers, Footnote [Text Block] |  |
| (1) | Amounts shown are the amounts of total compensation reported for Dr. Lee, our CEO, for column of the Summary Compensation Table (SCT).
| (2) | Amounts shown are the amounts of total compensation reported for Dr. Kirlin, our former CEO, for column of the Summary Compensation Table (SCT).
Adjustment To PEO Compensation, Footnote [Text Block] |  |
Compensation actually paid to PEO (3)
Year | Salary | Bonus | The fair value as of the end of the covered year for all stock and option awards that were granted during the year and that remain unvested as of the end of the covered year. | The change in fair value (whether positive or negative) as of the end of the covered year for any awards granted in any prior fiscal year that remain outstanding and unvested as of the end of the covered year. | The fair value as of the vesting date for any awards that were granted and vested in the covered fiscal year. | The change in fair value (whether positive or negative) as of the vesting date of any awards granted in any prior year for which all applicable vesting conditions were satisfied during the covered year. | Total
(a) | (b) | (c) | (d) | (e) | (f) | (h) | (i)
2023 | 750,000 | 1,300,000 | 2,203,200 | 289,688 | 0 | 69,013 | 4,611,901
2022 | 650,000 | 963,800 | 1,216,500 | 242,213 | 0 | (123,690) | 2,948,823
2021 | 459,530 | 365,000 | 454,650 | 128,335 | (165) | 10,514 | 1,417,864
| (3) | Amounts shown above include the compensation actually paid to Dr. Lee, our CEO.
Compensation actually paid to PEO (4)
Year | Income | Bonus | The fair value as of the end of the covered year for all stock and option awards that were granted during the year and that remain unvested as of the end of the covered year. | The change in fair value (whether positive or negative) as of the end of the covered year for any awards granted in any prior fiscal year that remain outstanding and unvested as of the end of the covered year. | The fair value as of the vesting date for any awards that were granted and vested in the covered fiscal year. | The change in fair value (whether positive or negative) as of the vesting date of any awards granted in any prior year for which all applicable vesting conditions were satisfied during the covered year. | Total
(a) | (b) | (c) | (d) | (e) | (f) | (h) | (i)
2023 | 168,462 | 0 | 0 | 0 | 0 | 0 | 168,462
2022 | 735,079 | 0 | 0 | 0 | 0 | (252,785) | 482,294
2021 | 649,544 | 425,000 | 0 | 299,925 | 0 | 96,586 | 1,471,055
| (4) | Amounts shown above include the compensation actually paid to Dr. Kirlin, our former CEO.
Non-PEO NEO Average Total Compensation Amount |  | $ 1,476,328 | $ 1,606,992 | $ 1,067,949
Non-PEO NEO Average Compensation Actually Paid Amount |  | $ 1,844,174 | 1,619,472 | 1,123,199
Compensation Actually Paid vs. Total Shareholder Return [Text Block] |  |  |  |
Compensation Actually Paid vs. Net Income [Text Block] |  |  |  |
Compensation Actually Paid vs. Company Selected Measure [Text Block] |  |  |  |
Total Shareholder Return Vs Peer Group [Text Block] |  |  |  |
Tabular List [Table Text Block] |  | Tabular List of Financial Performance Measures The Company considers the following to be the most important financial performance measures it uses to link actual compensation paid to its Named Executive Officers, for the periods 2021, 2022 and 2023 as set forth in the graphs above.
| ● | Net income
| ● | Gross Margin
| ● | EBITDA
Total Shareholder Return Amount |  | $ 188.31 | 166.36 | 133.24
Peer Group Total Shareholder Return Amount |  | 179.40 | 109.88 | 158.40
Net Income (Loss) Attributable to Parent |  | $ 125,500,000 | $ 118,800,000 | $ 55,400,000
Company Selected Measure Amount |  | 892,100,000 | 824,500,000 | 663,800,000
Measure [Axis]: 1 |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |
Measure Name |  | Net income |  |
Measure [Axis]: 2 |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |
Measure Name |  | Gross Margin |  |
Measure [Axis]: 3 |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |
Measure Name |  | EBITDA |  |
Dr. Lee |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |
PEO Total Compensation Amount | [1] | $ 4,061,200 | $ 2,924,350 | $ 1,272,800
PEO Actually Paid Compensation Amount | [2] | $ 4,611,901 | $ 2,948,823 | $ 1,417,864
Dr. Lee | PEO [Member] |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |
PEO Name |  | Dr. Lee | Dr. Lee | Dr. Lee
Dr. Lee | PEO [Member] | Salary |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |
Adjustment to Compensation Amount | [2] | $ 750,000 | $ 650,000 | $ 459,530
Dr. Lee | PEO [Member] | Bonus |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |
Adjustment to Compensation Amount | [2] | 1,300,000 | 963,800 | 365,000
Dr. Lee | PEO [Member] | The fair value as of the end of the covered year for all stock and option awards that were granted during the year and that remain unvested as of the end of the covered year. |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |
Adjustment to Compensation Amount | [2] | 2,203,200 | 1,216,500 | 454,650
Dr. Lee | PEO [Member] | The change in fair value (whether positive or negative) as of the end of the covered year for any awards granted in any prior fiscal year that remain outstanding and unvested as of the end of the covered year. |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |
Adjustment to Compensation Amount | [2] | 289,688 | 242,213 | 128,335
Dr. Lee | PEO [Member] | The fair value as of the vesting date for any awards that were granted and vested in the covered fiscal year. |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |
Adjustment to Compensation Amount | [2] | 0 | 0 | (165)
Dr. Lee | PEO [Member] | The change in fair value (whether positive or negative) as of the vesting date of any awards granted in any prior year for which all applicable vesting conditions were satisfied during the covered year. |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |
Adjustment to Compensation Amount | [2] | 69,013 | (123,690) | 10,514
Dr. Kirlin |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |
PEO Total Compensation Amount | [3] | 168,462 | 2,470,279 | 2,006,994
PEO Actually Paid Compensation Amount | [4] | $ 168,462 | $ 482,294 | $ 1,471,055
Dr. Kirlin | PEO [Member] |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |
PEO Name |  | Dr. Kirlin | Dr. Kirlin | Dr. Kirlin
Dr. Kirlin | PEO [Member] | Bonus |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |
Adjustment to Compensation Amount | [4] | $ 0 | $ 0 | $ 425,000
Dr. Kirlin | PEO [Member] | The fair value as of the end of the covered year for all stock and option awards that were granted during the year and that remain unvested as of the end of the covered year. |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |
Adjustment to Compensation Amount | [4] | 0 | 0 | 0
Dr. Kirlin | PEO [Member] | The change in fair value (whether positive or negative) as of the end of the covered year for any awards granted in any prior fiscal year that remain outstanding and unvested as of the end of the covered year. |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |
Adjustment to Compensation Amount | [4] | 0 | 0 | 299,925
Dr. Kirlin | PEO [Member] | The fair value as of the vesting date for any awards that were granted and vested in the covered fiscal year. |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |
Adjustment to Compensation Amount | [4] | 0 | 0 | 0
Dr. Kirlin | PEO [Member] | The change in fair value (whether positive or negative) as of the vesting date of any awards granted in any prior year for which all applicable vesting conditions were satisfied during the covered year. |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |
Adjustment to Compensation Amount | [4] | 0 | (252,785) | 96,586
Dr. Kirlin | PEO [Member] | Income |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |
Adjustment to Compensation Amount | [4] | $ 168,462 | $ 735,079 | $ 649,544
[1] | Amounts shown are the amounts of total compensation reported for Dr. Lee, our CEO, for column of the Summary Compensation Table (SCT).
[2] | Amounts shown above include the compensation actually paid to Dr. Lee, our CEO.
[3] | Amounts shown are the amounts of total compensation reported for Dr. Kirlin, our former CEO, for column of the Summary Compensation Table (SCT).
[4] | Amounts shown above include the compensation actually paid to Dr. Kirlin, our former CEO.

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iii + Details
Name: | ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph ii + Details
Name: | ecd_CompActuallyPaidVsNetIncomeTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i + Details
Name: | ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_MeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupTotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 6 + Details
Name: | ecd_TabularListTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnVsPeerGroupTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4 Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7 Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ecd_MeasureAxis=1
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=2
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=3
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=plab_DrLeeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_PeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=plab_SalaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=plab_BonusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=plab_TheFairValueAsOfTheEndOfTheCoveredYearForAllStockAndOptionAwardsThatWereGrantedDuringTheYearAndThatRemainUnvestedAsOfTheEndOfTheCoveredYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=plab_TheChangeInFairValueWhetherPositiveOrNegativeAsOfTheEndOfTheCoveredYearForAnyAwardsGrantedInAnyPriorFiscalYearThatRemainOutstandingAndUnvestedAsOfTheEndOfTheCoveredYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=plab_TheFairValueAsOfTheVestingDateForAnyAwardsThatWereGrantedAndVestedInTheCoveredFiscalYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=plab_TheChangeInFairValueWhetherPositiveOrNegativeAsOfTheVestingDateOfAnyAwardsGrantedInAnyPriorYearForWhichAllApplicableVestingConditionsWereSatisfiedDuringTheCoveredYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=plab_DrKirlinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=plab_IncomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |